AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Genelabs Technologies Inc.
Genelabs Technologies Inc., Redwood City, California, announced that it has been awarded a U.S. patent associated with the development of its anti-AIDS drug, GLQ223 (alpha-trichosanthin).
The patent covers a gene sequence encoding trichosanthin, as well as vectors to produce recombinant versions of this molecule. Use of trichosanthin and the family of related molecules in the treatment of AIDS is also covered by U.S. patents previously awarded to Genelabs in 1989.
"The patented technology ensures that we have a genetically engineered source for development and commercialization of this product," stated Frank F.C. …